A Phase 3 interventional study of Experimental: Tezepelumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 72 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.
Among the 28 studies testing tezepelumab in Asthma, this one is the 5th largest by enrollment, is one of 5 that started in 2019, is one of 16 in phase 3, and was the 9th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–55
AstraZeneca · Sites in China
Ages 12–80
AstraZeneca · Sites in United States, Argentina, Brazil and 19 more countries
Ages 5–11
Qianfoshan Hospital · Sites in China
Ages 18–75
Qilu Pharmaceutical Co., Ltd.
Ages 18–80
By country, each count listing its studies:
tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 5 started in 2019.
This study's enrollment of 405 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 121 across the 28 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 85th largest by enrollment of the 248 interventional ones that give a count, is one of 24 that started in 2019, is one of 121 in phase 3, and was the 254th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing tezepelumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
| NCT07757841Qianfoshan HospitalReal-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing tezepelumab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma
This is a regional, multicentre, randomized, double-blind, placebo controlled, parallel group, phase 3 study designed to evaluate the efficacy and safety of 210 mg Q4W (SC) of tezepelumab in adults with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 396 participants will be randomized regionally (China/non-China). Participants will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tezepelumab: Tezepelumab subcutaneous injection
Biological: Experimental: Tezepelumab
Placebo: Placebo subcutaneous injection
Other: Placebo
Tezepelumab subcutaneous injection
Also known as: Tezepelumab
Placebo subcutaneous injection
Annual Asthma Exacerbation Rate (AERR)
The annual exacerbation rate is based on exacerbations reported by the investigator in the eCRF over 52 weeks
Time frame: Randomization to Week 52
Mean Change From Baseline in Pre-dose/Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 52
Mean change from baseline in FEV1 as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.
Time frame: Randomization to Week 52
Mean Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score at Week 52
Mean change from baseline in AQLQ(S)+12 as compared to placebo at Week 52. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma participants. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).
Time frame: Randomization to Week 52
Mean Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score at Week 52
Mean change from baseline in ACQ-6 as compared to placebo at Week 52. The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.
Time frame: Randomization to Week 52
Mean Change From Baseline in Weekly Mean Daily Asthma Symptom Diary Score at Week 52
Mean change from baseline in Asthma Symptom Diary score as compared to placebo at Week 52. The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. A higher value indicates a worse outcome. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4.
Time frame: Randomization to Week 52
Time to First Asthma Exacerbation
Time to the first occurrence of asthma exacerbation post randomization, presented as number of participants with at least one asthma exacerbation reported in the eCRF
Time frame: Randomization to Week 52
Mean Change From Baseline in Fractional Exhaled Nitric Oxide at Week 52
Mean change from baseline in FENO (ppb) at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers
Time frame: Randomization to Week 52
Number of Participants With Asthma Specific Resource Utilization Over 52 Weeks
Number of participants with asthma specific resource utilization (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) over 52 weeks.
Time frame: Randomization to Week 52
Pharmacokinetics of Tezepelumab
Mean serum trough PK concentrations taken pre-dose at each scheduled visit to evaluate the pharmacokinetics (PK) of tezepelumab
Time frame: Baseline, Week 24, Week 52, Week 64
Mean Change From Baseline in EQ-5D-5L VAS Score at Week 52
Mean change from baseline in EQ-5D-5L VAS at week 52. EQ-5D-5L visual analogue scale (VAS) allows participants to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.
Time frame: At Week 52
Mean Change From Baseline in Blood Eosinophils (Cells/uL) at Week 52
Mean change from baseline in blood eosinophil counts at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers.
Time frame: Randomization to Week 52
Mean Change From Baseline in Total Serum IgE (IU/mL) at Week 52
Mean change from baseline in IgE at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers.
Time frame: Randomization to Week 52
Mean Change From Baseline in Night Time Awakenings (Percentage) at Week 52
Mean change from baseline in night time awakenings due to asthma at Week 52. Night time awakenings percentage is defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with available data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean.
Time frame: Randomization to Week 52
Immunogenicity of Tezepelumab
Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.
Time frame: Baseline to Week 64
Mean Change From Baseline in Daily Rescue Medication Use (Weekly Means) at Week 52
Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x \[number of night nebulizer times\] + number of daytime inhaler puffs + 2 x \[number of day nebulizer times\]. Weekly means are calculated using at least 4 of 7 days of daily rescue medication use.
Time frame: Randomization to Week 52
Mean Change From Baseline in Home Based Morning Peak Expiratory Flow (PEF) at Week 52
Mean change from baseline in home based morning PEF (L/min) at Week 52. Home PEF testing was performed by participant in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.
Time frame: Randomization to Week 52
Mean Change From Baseline in Home Based Evening Peak Expiratory Flow (PEF) at Week 52
Mean change from baseline in home based evening PEF (L/min) at Week 52. Home PEF testing was performed by participant in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.
Time frame: Randomization to Week 52
Annual Asthma Exacerbation Rate Resulting in Emergency Room Visit or Hospitalization
The annual exacerbation rate is based on exacerbations reported by the investigator that are associated with an emergency room visit, urgent care visit, or a hospitalization (where urgent care visit was captured as an emergency room visit on the eCRF).
Time frame: Randomization to Week 52
Proportion of Participants Who Had no Asthma Exacerbations
The proportion of participants who had no asthma exacerbations is presented as the percentage of participants with no exacerbations. This is defined as participants who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation during this period.
Time frame: Randomization to Week 52
A total of 401 participants were randomized at 74 sites in 3 Asian countries to receive treatment with tezepelumab 210mg Q4W or placebo.
| Milestone | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Started | 201 | 199 |
| Completed | 186 | 168 |
| Not completed | 15 | 31 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal by subject | 8 | 21 |
| Withdrew: Due to covid-19 pandemic | 5 | 2 |
| Withdrew: Protocol-specified withdrawal criterion met | 0 | 2 |
| Withdrew: Other than above | 0 | 1 |
The annual exacerbation rate is based on exacerbations reported by the investigator in the eCRF over 52 weeks
| Events per year | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Annual Asthma Exacerbation Rate (AERR) | 0.42 (0.30 to 0.59) | 1.63 (1.22 to 2.19) |
Mean change from baseline in FEV1 as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.
| Litre | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in Pre-dose/Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | 0.35 ± 0.029 | 0.11 ± 0.030 |
Mean change from baseline in AQLQ(S)+12 as compared to placebo at Week 52. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma participants. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).
| Scores on a scale | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score at Week 52 | 1.29 ± 0.074 | 0.94 ± 0.076 |
Mean change from baseline in ACQ-6 as compared to placebo at Week 52. The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.
| Scores on a scale | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score at Week 52 | -1.34 ± 0.058 | -1.03 ± 0.059 |
Mean change from baseline in Asthma Symptom Diary score as compared to placebo at Week 52. The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. A higher value indicates a worse outcome. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4.
| Scores on a scale | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in Weekly Mean Daily Asthma Symptom Diary Score at Week 52 | -0.61 ± 0.036 | -0.44 ± 0.037 |
Time to the first occurrence of asthma exacerbation post randomization, presented as number of participants with at least one asthma exacerbation reported in the eCRF
| Participants | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Time to First Asthma Exacerbation | 45 | 89 |
Mean change from baseline in FENO (ppb) at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers
| ppb | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in Fractional Exhaled Nitric Oxide at Week 52 | -15.88 ± 1.628 | -3.15 ± 1.658 |
Number of participants with asthma specific resource utilization (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) over 52 weeks.
| Participants | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Hospitalisation | 4 | 13 |
| Emergency room visit | 5 | 11 |
| Unscheduled visit to specialist | 36 | 75 |
| Home visit | 1 | 0 |
| Telephone call | 28 | 55 |
| Ambulance transport | 0 | 2 |
Mean serum trough PK concentrations taken pre-dose at each scheduled visit to evaluate the pharmacokinetics (PK) of tezepelumab
| ug/mL | Tezepelumab 210mg Q4W |
|---|---|
| Baseline | 0 ± 0 |
| Week 24 | 21.3513 ± 43.96 |
| Week 52 | 21.2222 ± 41.51 |
| Week 64 | 1.4450 ± 157.46 |
Mean change from baseline in EQ-5D-5L VAS at week 52. EQ-5D-5L visual analogue scale (VAS) allows participants to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.
| Scores on a scale | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in EQ-5D-5L VAS Score at Week 52 | 12.80 ± 1.009 | 9.67 ± 1.028 |
Mean change from baseline in blood eosinophil counts at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers.
| cells/uL | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in Blood Eosinophils (Cells/uL) at Week 52 | -193.44 ± 21.538 | -38.86 ± 21.984 |
Mean change from baseline in IgE at week 52 to assess the effect of 210 mg of tezepelumab SC Q4W on biomarkers.
| IU/mL | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in Total Serum IgE (IU/mL) at Week 52 | -92.77 ± 27.460 | 0.30 ± 28.013 |
Mean change from baseline in night time awakenings due to asthma at Week 52. Night time awakenings percentage is defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with available data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean.
| Percentage of nights with awakenings | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in Night Time Awakenings (Percentage) at Week 52 | -18.74 ± 1.035 | -15.99 ± 1.093 |
Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.
| Participants | Tezepelumab 210mg Q4W (China Cohort) | Placebo (China Cohort) | Tezepelumab 210mg Q4W (Non-China Cohort) | Placebo (Non-China Cohort) |
|---|---|---|---|---|
| ADA positive at baseline and/or post-baseline | 11 | 18 | 3 | 7 |
| Any baseline ADA positive | 10 | 14 | 2 | 5 |
| Only baseline ADA positive | 10 | 7 | 2 | 5 |
| Any post-baseline ADA positive | 1 | 11 | 1 | 2 |
| Both baseline and at least one post-baseline ADA positive | 0 | 7 | 0 | 0 |
| Treatment-induced ADA positive | 1 | 4 | 1 | 2 |
| Treatment-boosted ADA positive | 0 | 1 | 1 | 0 |
| TE-ADA positive | 1 | 5 | 1 | 2 |
| ADA persistently positive | 1 | 10 | 1 | 1 |
| ADA transiently positive | 0 | 1 | 0 | 1 |
Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x \[number of night nebulizer times\] + number of daytime inhaler puffs + 2 x \[number of day nebulizer times\]. Weekly means are calculated using at least 4 of 7 days of daily rescue medication use.
| Inhalations and nebulizers per week | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in Daily Rescue Medication Use (Weekly Means) at Week 52 | -0.81 ± 0.064 | -0.70 ± 0.066 |
Mean change from baseline in home based morning PEF (L/min) at Week 52. Home PEF testing was performed by participant in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.
| L/min | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in Home Based Morning Peak Expiratory Flow (PEF) at Week 52 | 46.70 ± 4.586 | 18.96 ± 4.730 |
Mean change from baseline in home based evening PEF (L/min) at Week 52. Home PEF testing was performed by participant in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.
| L/min | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Mean Change From Baseline in Home Based Evening Peak Expiratory Flow (PEF) at Week 52 | 42.14 ± 4.558 | 16.81 ± 4.700 |
The annual exacerbation rate is based on exacerbations reported by the investigator that are associated with an emergency room visit, urgent care visit, or a hospitalization (where urgent care visit was captured as an emergency room visit on the eCRF).
| Events per year | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Annual Asthma Exacerbation Rate Resulting in Emergency Room Visit or Hospitalization | 0.07 (0.03 to 0.15) | 0.18 (0.09 to 0.34) |
The proportion of participants who had no asthma exacerbations is presented as the percentage of participants with no exacerbations. This is defined as participants who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation during this period.
| Percentage | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Proportion of Participants Who Had no Asthma Exacerbations | 74.6 | 50.3 |
Collected over Adverse events is collected from time of signature of the informed consent form until end of study at Week 64.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tezepelumab 210mg Q4W | 0/201 (0%) | 16/201 (8%) | 114/201 (56.7%) |
| Placebo | 2/199 (1%) | 36/199 (18.1%) | 125/199 (62.8%) |
| Event | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 4/201 | 17/199 |
| PneumoniaInfections and infestations | 1/201 | 4/199 |
| Ovarian cyst rupturedReproductive system and breast disorders | 2/201 | 0/199 |
| Large intestine polypGastrointestinal disorders | 0/201 | 1/199 |
| Salivary gland massGastrointestinal disorders | 0/201 | 1/199 |
| DeathGeneral disorders | 0/201 | 1/199 |
| AppendicitisInfections and infestations | 0/201 | 1/199 |
| Covid-19Infections and infestations | 0/201 | 1/199 |
| Chronic sinusitisInfections and infestations | 0/201 | 1/199 |
| Coronavirus pneumoniaInfections and infestations | 0/201 | 1/199 |
| Event | Tezepelumab 210mg Q4W | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 71/201 | 68/199 |
| Covid-19Infections and infestations | 29/201 | 25/199 |
| Suspected covid-19Infections and infestations | 16/201 | 25/199 |
| NasopharyngitisInfections and infestations | 11/201 | 16/199 |
| PneumoniaInfections and infestations | 3/201 | 9/199 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 3/201 | 9/199 |
| Respiratory tract infectionInfections and infestations | 1/201 | 8/199 |
| BronchitisInfections and infestations | 6/201 | 7/199 |
| PharyngitisInfections and infestations | 2/201 | 7/199 |
| Pneumonia bacterialInfections and infestations | 3/201 | 7/199 |
| Age, Categorical(Participants) | Tezepelumab 210mg Q4W | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 166 | 167 | 333 |
| >=65 years | 35 | 32 | 67 |
| Age, Continuous(Years) | Tezepelumab 210mg Q4W | Placebo | Total |
|---|---|---|---|
| Mean | 52.3 ± 12.4 | 54.3 ± 10.3 | 53.3 ± 11.4 |
| Sex: Female, Male(Participants) | Tezepelumab 210mg Q4W | Placebo | Total |
|---|---|---|---|
| Female | 119 | 112 | 231 |
| Male | 82 | 87 | 169 |
| Ethnicity (NIH/OMB)(Participants) | Tezepelumab 210mg Q4W | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 201 | 199 | 400 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Tezepelumab 210mg Q4W | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 201 | 199 | 400 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jun 2019 to primary completion in May 2024, 59 months.
Results were first posted in Jul 2025, 1 year 1 month after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 59 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab